Fortrea Holdings (FTRE) Cash from Investing Activities (2022 - 2026)
Fortrea Holdings (FTRE) posted Cash from Investing Activities of -$8.0 million for Q1 2026, down 6.67% on a QoQ basis from -$7.5 million in Q4 2025, and down 149.69% year-over-year from $16.1 million in Q1 2025.
Fortrea Holdings (FTRE) Cash from Investing Activities (2022 - 2026) Analysis & Trends
Fortrea Holdings' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$8.0 million for Q1 2026.
- Quarterly Cash from Investing Activities fell 149.69% year-over-year to -$8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.7 million (down 103.5% YoY) and the FY2025 annual result came in at $14.4 million, down 94.28% from the prior year.
- Cash from Investing Activities was -$8.0 million for Q1 2026 at Fortrea Holdings, down from -$7.5 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $265.4 million in Q2 2024 and bottomed at -$18.4 million in Q4 2022.
- A 5-year average of $12.7 million and a median of -$8.0 million in 2026 frame the typical range for Cash from Investing Activities.
- Peak annual rise in Cash from Investing Activities reached 2953.76% in 2024, while the deepest fall reached 400.0% in 2024.
- Fortrea Holdings' Cash from Investing Activities stood at -$18.4 million in 2022, then soared by 51.09% to -$9.0 million in 2023, then surged by 138.89% to $3.5 million in 2024, then tumbled by 314.29% to -$7.5 million in 2025, then declined by 6.67% to -$8.0 million in 2026.
- Business Quant data shows FTRE's Cash from Investing Activities at -$8.0 million in Q1 2026, -$7.5 million in Q4 2025, and $13.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Fortrea Holdings | 1.81 Bn | 1.67 Bn | 123.60 Mn | -8.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.00 Mn |
| Mar 31, 2026 | -8.00 Mn |
| Dec 31, 2025 | -7.50 Mn |
| Dec 31, 2025 | -7.50 Mn |
| Sep 30, 2025 | 13.30 Mn |
| Sep 30, 2025 | 13.30 Mn |
| Jun 30, 2025 | -7.50 Mn |
| Jun 30, 2025 | -7.50 Mn |
| Mar 31, 2025 | 16.10 Mn |
| Mar 31, 2025 | 16.10 Mn |
| Dec 31, 2024 | 3.50 Mn |
| Dec 31, 2024 | 3.50 Mn |
| Sep 30, 2024 | -8.10 Mn |
| Sep 30, 2024 | -8.10 Mn |
| Jun 30, 2024 | 265.40 Mn |
| Jun 30, 2024 | 265.40 Mn |
| Mar 31, 2024 | -9.20 Mn |
| Mar 31, 2024 | -9.20 Mn |
| Dec 31, 2023 | -9.00 Mn |
| Dec 31, 2023 | -9.00 Mn |